Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT03423953
Active, not recruiting Observational

Comprehensive Nano - Post Market Clinical Follow-Up Study

NCT03423953 · tracked via the Priya Life Science South Korea tracker
Sponsor
Zimmer Biomet
Phase
Observational
Started
2013-10-30
Last updated
2026-04-21

Condition(s) studied

OsteoarthritisAvascular NecrosisRheumatoid ArthritisRevisionCorrection of Functional Deformity

Investigational drug(s) / intervention(s)

Comprehensive Nano

Comprehensive Nano: Patients requiring the Comprehensive Nano shoulder system.

Study summary

This data collection project is intended to provide clinical outcomes data to engineering, marketing as well as fulfill the post market surveillance requirements of various regulatory authorities. The study will be a prospective and one-arm.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis. * Rheumatoid arthritis * Revision where other devices or treatments have failed * Correction of functional deformity. * Difficult clinical management problems where other methods of treatment may not be suitable or may be inadequate * Difficult clinical management problems where other methods of treatment may not be suitable or may be inadequate Exclusion Criteria: * Infection * Sepsis * osteomyelitis

Primary outcome measure(s)

  • Survivorship — 10 years
    Kaplan Meier method

Trial sites (5)

FacilityCityRegionStatus
Privatklinik Leech Graz Styria
Kingston General Hospital Kingston Ontario
Chonnam National University Hospital Gwangju Gwangju
Samsung Medical Centre Seoul Seoul
University of Liverpool Liverpool Merseyside

More Zimmer Biomet trials in South Korea

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System Active, not recruiting
G7 Dual Mobility With Vivacit-E or Longevity PMCF Enrolling by invitation
RibFix Blu Thoracic Fixation System Versus Non-surgical Treatment in Non-flail Chest Rib Fractures Recruiting
G7 Dual Mobility System Used in Total Hip Arthroplasty for the Treatment of Femoral Neck Fracture Active, not recruiting

Other trials for the same condition

Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage Active, not recruiting
Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System Active, not recruiting
G7 Dual Mobility With Vivacit-E or Longevity PMCF Enrolling by invitation
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis Recruiting
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03423953 on ClinicalTrials.gov ↗ ← All trials in South Korea